Return-Path: <engelbert.mephu_nguifo@uca.fr>
X-Original-To: polytech_liste-egc@sympa6.univ-nantes.prive
Delivered-To: polytech_liste-egc@sympa6.univ-nantes.prive
Received: from bouncesmtp2.univ-nantes.fr (BounceSMTP2.univ-nantes.prive [172.20.12.67])
	by sympa6.univ-nantes.prive (Postfix) with ESMTP id A9CDC2292950
	for <polytech_liste-egc@sympa6.univ-nantes.prive>; Fri, 22 Feb 2019 11:25:55 +0100 (CET)
Received: from mx2.d101.univ-nantes.fr (MX2.univ-nantes.fr [193.52.101.136])
	by bouncesmtp2.univ-nantes.fr (Postfix) with ESMTP id A12DD664315
	for <polytech_liste-egc@sympa6.univ-nantes.prive>; Fri, 22 Feb 2019 11:25:55 +0100 (CET)
Received: from localhost (localhost [127.0.0.1])
	by mx2.d101.univ-nantes.fr (Postfix) with ESMTP id 99C47B190AF
	for <liste-egc@polytech.univ-nantes.fr>; Fri, 22 Feb 2019 11:25:55 +0100 (CET)
X-Virus-Scanned: Debian amavisd-new at univ-nantes.fr
X-Spam-Flag: NO
X-Spam-Score: 0.32
X-Spam-Level:
X-Spam-Status: No, score=0.32 tagged_above=-1000 required=5
	tests=[CRM114_UNSURE=0.1, DKIM_SIGNED=0.1, DKIM_VALID=-0.1,
	DKIM_VALID_AU=-0.1, HTML_MESSAGE=0.001, MR_NOT_ATTRIBUTED_IP=0.2,
	NO_RDNS2=0.01, RCVD_IN_DNSWL_NONE=-0.0001, RCVD_IN_WSFF=0.01,
	SPF_PASS=-0.001, UN_PHISHING_PW=0.1] autolearn=disabled
X-CRM114-Status: UNSURE ( -4.4729 )
X-CRM114-CacheID: 
Authentication-Results: univ-nantes.fr (amavisd-new); dkim=pass (1024-bit key)
	header.d=uca.fr
Received: from mx2.d101.univ-nantes.fr ([127.0.0.1])
	by localhost (univ-nantes.fr [127.0.0.1]) (amavisd-new, port 10024)
	with ESMTP id m77CTqDPzmzY for <liste-egc@polytech.univ-nantes.fr>;
	Fri, 22 Feb 2019 11:25:51 +0100 (CET)
X-Greylist: domain auto-whitelisted by SQLgrey-1.6.7
Received: from mta01.udamail.fr (mta01.udamail.fr [193.49.117.20])
	by mx2.d101.univ-nantes.fr (Postfix) with ESMTPS id 701FF6523E0
	for <liste-egc@polytech.univ-nantes.fr>; Fri, 22 Feb 2019 11:25:51 +0100 (CET)
Received: from mta01.udamail.fr (localhost.localdomain [127.0.0.1])
	by mta01.udamail.fr (Postfix) with ESMTPS id 445SCx4QBrzBrPl
	for <liste-egc@polytech.univ-nantes.fr>; Fri, 22 Feb 2019 11:25:49 +0100 (CET)
Received: from localhost (localhost.localdomain [127.0.0.1])
	by mta01.udamail.fr (Postfix) with ESMTP id 445SCx3nVKzBrS2
	for <liste-egc@polytech.univ-nantes.fr>; Fri, 22 Feb 2019 11:25:49 +0100 (CET)
DKIM-Filter: OpenDKIM Filter v2.10.3 mta01.udamail.fr 445SCx3nVKzBrS2
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=uca.fr;
	s=72FD7F0C-5358-11E8-A3B7-17E0B3BFED1B; t=1550831149;
	bh=Dmwyq7eIaJO9PxU5fls6lAC3McWGeRZf343T10FKFaQ=;
	h=Date:From:To:Message-ID:MIME-Version;
	b=ErWH40j+SI3JRO7fSDD0AHsJl2qEGg2yqsYPibs3KIDJ//6vYuUIikZ40TgCHeJ1z
	 BUKQZrpg09ZajTFw3t+EBkcJltlclFrwaDc7tUMXu7aDWrba3rdlLZVBJjlSTJMSkm
	 O1wqt8Rs2mKEo6qhlUUyXVBQnbfQEVzAX82fj3VY=
X-Virus-Scanned: amavisd-new at mta01.udamail.fr
Received: from mta01.udamail.fr ([127.0.0.1])
	by localhost (mta01.udamail.fr [127.0.0.1]) (amavisd-new, port 10026)
	with ESMTP id bIhl6jKY-B95 for <liste-egc@polytech.univ-nantes.fr>;
	Fri, 22 Feb 2019 11:25:49 +0100 (CET)
Received: from store12.udamail.fr (store12.udamail.fr [192.168.58.22])
	by mta01.udamail.fr (Postfix) with ESMTP id 445SCx2zxdzBrPl
	for <liste-egc@polytech.univ-nantes.fr>; Fri, 22 Feb 2019 11:25:49 +0100 (CET)
Date: Fri, 22 Feb 2019 11:25:49 +0100 (CET)
From: Engelbert MEPHU NGUIFO <engelbert.mephu_nguifo@uca.fr>
To: liste-egc@polytech.univ-nantes.fr
Message-ID: <2037914279.3039231.1550831149257.JavaMail.zimbra@uca.fr>
In-Reply-To: <1607980459.3028103.1550830206873.JavaMail.zimbra@uca.fr>
References: <2123816044.3021096.1550829672539.JavaMail.zimbra@uca.fr> <2103376019.3025659.1550830005465.JavaMail.zimbra@uca.fr> <1607980459.3028103.1550830206873.JavaMail.zimbra@uca.fr>
MIME-Version: 1.0
Content-Type: multipart/alternative; 
	boundary="=_810fdb11-1c3a-431f-9e54-ccfdcd2dd129"
X-Originating-IP: [109.8.53.142]
X-Mailer: Zimbra 8.8.9_GA_3717 (ZimbraWebClient - GC72 (Mac)/8.8.9_GA_3042)
Thread-Topic: PhD Proposal
Thread-Index: gqFNttQwnTBfRjPRnRFI2cNuNaVImlmd5BQkyS2Anc9nM1S9EQ==
X-Validation-by: p_bruneau@hotmail.com
Subject: [liste-egc] PhD Proposal

--=_810fdb11-1c3a-431f-9e54-ccfdcd2dd129
Content-Type: text/plain; charset=utf-8
Content-Transfer-Encoding: quoted-printable





PhD Proposal: Development of machine learning algorithms for the identifica=
tion of biomarkers of neurotoxicity.=20



Context : H2020 Project NeuroDeRisk=20

Advisors : Engelbert Mephu Nguifo ( [ mailto:engelbert.mephu_nguifo@uca.fr =
| engelbert.mephu_nguifo@uca.fr ] )=20

Vincent Barra ( [ mailto:vincent.barra@isima.fr | vincent.barra@isima.fr ] =
)=20



Location : LIMOS, UMR 6158 CNRS ( [ https://limos.fr/ | https://limos.fr/ ]=
 )=20

Clermont-Auvergne University=20

Scientific Campus, 1 rue de la Ch=C3=A9barde=20

63178 AUBIERE =E2=80=93 FRANCE=20



Dates : September 2019-August 2022=20



There is still a lack of complete understanding of the complex pathways and=
 mechanisms leading to central and peripheral drug-induced neurotoxicity. H=
owever, these adverse effects are to a considerable extent (up to 25%) resp=
onsible for failure in clinical trials, affecting volunteers or patients ad=
ministered with experimental drugs, and also, to some extent, albeit less t=
han 1%, for hospitalizations caused by hidden neurotoxic adverse effects of=
 marketed drugs.=20



The ambition of NeuroDeRisk [ https://mail.uca.fr/zimbra/mail#_edn1 | [i] ]=
 H2020 project is to bundle the scientific expertise of experimental and th=
eoretical scientists and to collaborate with computer scientists to address=
 the challenge of preclinical prediction of neurotoxicity using a fully int=
egrated approach: by linking unique expertise for building in vitro and in =
vivo models with in silico prediction tools, the project will establish a n=
ovel and validated toolbox for preclinical prediction of neurotoxicity in h=
umans.=20



The PhD subject is centered on the development of new machine learning stra=
tegies to optimize the identification of predictive and alerting biomarkers=
 of neurotoxicity . The objectives here will be:=20

- to classify subjects (with respect to neurotoxicity based on data collect=
ed by previous extensive behavioral and biochemical signatures of neurotoxi=
city in vivo , in vitro and ex vivo) ;=20

- to compute low dimensional manifolds on which subjects lie, and be able t=
o explore the trends and directions of all possible neurotoxic effects in t=
he derived space ;=20

- to be able to early predict biomarkers of neurotoxicity, based on only a =
subset of data or on new features derived from the original data.=20

Both classical and innovative machine learning algorithms will be explored.=
=20



Having selected the most promising biomarker candidates from in vivo, in vi=
tro, and ex vivo studies, in silico prediction of biomarkers using a suitab=
ly modified version of a predictive platform will be performed. Additional =
bioinformatics tools will be used in biomarker validation and prioritizatio=
n by other partners of the European project.=20








[ https://mail.uca.fr/zimbra/mail#_ednref1 | [i] ] NeuroDeRisk (Neurotoxici=
ty De-Risking in Preclinical Drug Discovery) is a H2020 European Project ga=
thering 19 partners from 13 countries.=20


--=_810fdb11-1c3a-431f-9e54-ccfdcd2dd129
Content-Type: text/html; charset=utf-8
Content-Transfer-Encoding: quoted-printable

<html><body><div style=3D"font-family: arial, helvetica, sans-serif; font-s=
ize: 10pt; color: #000000"><div><style>
<!--
=20
 @font-face
=09{font-family:Wingdings;
=09panose-1:5 0 0 0 0 0 0 0 0 0;
=09mso-font-charset:2;
=09mso-generic-font-family:decorative;
=09mso-font-pitch:variable;
=09mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
=09{font-family:"Cambria Math";
=09panose-1:2 4 5 3 5 4 6 3 2 4;
=09mso-font-charset:0;
=09mso-generic-font-family:roman;
=09mso-font-pitch:variable;
=09mso-font-signature:3 0 0 0 1 0;}
@font-face
=09{font-family:Calibri;
=09panose-1:2 15 5 2 2 2 4 3 2 4;
=09mso-font-charset:0;
=09mso-generic-font-family:swiss;
=09mso-font-pitch:variable;
=09mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
=09{font-family:"Arial Narrow";
=09panose-1:2 11 6 6 2 2 2 3 2 4;
=09mso-font-charset:0;
=09mso-generic-font-family:swiss;
=09mso-font-pitch:variable;
=09mso-font-signature:647 2048 0 0 159 0;}
=20
 p.MsoNormal, li.MsoNormal, div.MsoNormal
=09{mso-style-unhide:no;
=09mso-style-qformat:yes;
=09mso-style-parent:"";
=09margin:0cm;
=09margin-bottom:.0001pt;
=09mso-pagination:widow-orphan;
=09font-size:12.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
span.MsoEndnoteReference
=09{mso-style-noshow:yes;
=09mso-style-priority:99;
=09vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
=09{mso-style-noshow:yes;
=09mso-style-priority:99;
=09mso-style-link:"Note de fin Car";
=09margin:0cm;
=09margin-bottom:.0001pt;
=09mso-pagination:widow-orphan;
=09font-size:10.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
=09{mso-style-priority:99;
=09color:#0563C1;
=09mso-themecolor:hyperlink;
=09text-decoration:underline;
=09text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
=09{mso-style-noshow:yes;
=09mso-style-priority:99;
=09color:#954F72;
=09mso-themecolor:followedhyperlink;
=09text-decoration:underline;
=09text-underline:single;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
=09{mso-style-priority:34;
=09mso-style-unhide:no;
=09mso-style-qformat:yes;
=09margin-top:0cm;
=09margin-right:0cm;
=09margin-bottom:0cm;
=09margin-left:36.0pt;
=09margin-bottom:.0001pt;
=09mso-add-space:auto;
=09mso-pagination:widow-orphan;
=09font-size:12.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
=09{mso-style-priority:34;
=09mso-style-unhide:no;
=09mso-style-qformat:yes;
=09mso-style-type:export-only;
=09margin-top:0cm;
=09margin-right:0cm;
=09margin-bottom:0cm;
=09margin-left:36.0pt;
=09margin-bottom:.0001pt;
=09mso-add-space:auto;
=09mso-pagination:widow-orphan;
=09font-size:12.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
=09{mso-style-priority:34;
=09mso-style-unhide:no;
=09mso-style-qformat:yes;
=09mso-style-type:export-only;
=09margin-top:0cm;
=09margin-right:0cm;
=09margin-bottom:0cm;
=09margin-left:36.0pt;
=09margin-bottom:.0001pt;
=09mso-add-space:auto;
=09mso-pagination:widow-orphan;
=09font-size:12.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
=09{mso-style-priority:34;
=09mso-style-unhide:no;
=09mso-style-qformat:yes;
=09mso-style-type:export-only;
=09margin-top:0cm;
=09margin-right:0cm;
=09margin-bottom:0cm;
=09margin-left:36.0pt;
=09margin-bottom:.0001pt;
=09mso-add-space:auto;
=09mso-pagination:widow-orphan;
=09font-size:12.0pt;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
span.NotedefinCar
=09{mso-style-name:"Note de fin Car";
=09mso-style-noshow:yes;
=09mso-style-priority:99;
=09mso-style-unhide:no;
=09mso-style-locked:yes;
=09mso-style-link:"Note de fin";
=09mso-ansi-font-size:10.0pt;
=09mso-bidi-font-size:10.0pt;}
.zimbra1
=09{mso-style-type:export-only;
=09mso-default-props:yes;
=09font-family:"Calibri",sans-serif;
=09mso-ascii-font-family:Calibri;
=09mso-ascii-theme-font:minor-latin;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-hansi-font-family:Calibri;
=09mso-hansi-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;
=09mso-fareast-language:EN-US;}
=20
 @page
=09{mso-footnote-separator: ecs;}
@page WordSection1
=09{size:595.0pt 842.0pt;
=09margin:70.85pt 70.85pt 70.85pt 70.85pt;
=09mso-header-margin:35.4pt;
=09mso-footer-margin:35.4pt;
=09mso-paper-source:0;}
div.WordSection1
=09{page:WordSection1;}
=20
 @list l0
=09{mso-list-id:1826435012;
=09mso-list-type:hybrid;
=09mso-list-template-ids:1808438476 -387563796 67895299 67895301 67895297 6=
7895299 67895301 67895297 67895299 67895301;}
@list l0:level1
=09{mso-level-start-at:0;
=09mso-level-number-format:bullet;
=09mso-level-text:-;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:"Arial Narrow",sans-serif;
=09mso-fareast-font-family:Calibri;
=09mso-fareast-theme-font:minor-latin;
=09mso-bidi-font-family:"Times New Roman";
=09mso-bidi-theme-font:minor-bidi;}
@list l0:level2
=09{mso-level-number-format:bullet;
=09mso-level-text:o;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:"Courier New";}
@list l0:level3
=09{mso-level-number-format:bullet;
=09mso-level-text:=EF=82=A7;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:Wingdings;}
@list l0:level4
=09{mso-level-number-format:bullet;
=09mso-level-text:=EF=82=B7;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:Symbol;}
@list l0:level5
=09{mso-level-number-format:bullet;
=09mso-level-text:o;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:"Courier New";}
@list l0:level6
=09{mso-level-number-format:bullet;
=09mso-level-text:=EF=82=A7;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:Wingdings;}
@list l0:level7
=09{mso-level-number-format:bullet;
=09mso-level-text:=EF=82=B7;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:Symbol;}
@list l0:level8
=09{mso-level-number-format:bullet;
=09mso-level-text:o;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:"Courier New";}
@list l0:level9
=09{mso-level-number-format:bullet;
=09mso-level-text:=EF=82=A7;
=09mso-level-tab-stop:none;
=09mso-level-number-position:left;
=09text-indent:-18.0pt;
=09font-family:Wingdings;}
ol
=09{margin-bottom:0cm;}
ul
=09{margin-bottom:0cm;}
-->
</style></div><div><br data-mce-bogus=3D"1"></div><div data-marker=3D"__QUO=
TED_TEXT__"><div style=3D"font-family: arial, helvetica, sans-serif; font-s=
ize: 10pt; color: #000000"><div></div><div><b style=3D"font-family: Calibri=
, sans-serif; font-size: 12pt;"><span lang=3D"EN-US" style=3D"font-size: 18=
.0pt; font-family: 'Arial Narrow',sans-serif; color: #323e4f; mso-themecolo=
r: text2; mso-themeshade: 191; letter-spacing: .2pt; mso-ansi-language: EN-=
US;">&nbsp;</span></b><br></div><div><div style=3D"font-family: arial, helv=
etica, sans-serif; font-size: 10pt; color: #000000"><div><div style=3D"font=
-family: arial, helvetica, sans-serif; font-size: 10pt; color: #000000"><di=
v><div id=3D"zimbraEditorContainer" style=3D"font-family: arial, helvetica,=
 sans-serif; font-size: 10pt; color: #000000" class=3D"1"><p class=3D"MsoNo=
rmal" align=3D"center" style=3D"text-align: center; margin: 0px;"><b style=
=3D"mso-bidi-font-weight: normal;"><span lang=3D"EN-US" style=3D"font-size:=
 18.0pt; font-family: 'Arial Narrow',sans-serif; color: #323e4f; mso-themec=
olor: text2; mso-themeshade: 191; letter-spacing: .2pt; mso-ansi-language: =
EN-US;">PhD Proposal: Development of machine learning algorithms for the id=
entification of biomarkers of neurotoxicity.</span></b></p><p class=3D"MsoN=
ormal" align=3D"center" style=3D"text-align: center; margin: 0px;"><span la=
ng=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-f=
amily: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-s=
tyle: italic;">&nbsp;</span></p><p class=3D"MsoNormal" align=3D"center" sty=
le=3D"text-align: center; margin: 0px;"><i><span lang=3D"EN-US" style=3D"fo=
nt-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sa=
ns-serif; mso-ansi-language: EN-US;">Context</span></i><span lang=3D"EN-US"=
 style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Aria=
l Narrow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-style: italic=
;"> : H2020 Project NeuroDeRisk</span></p><p class=3D"MsoNormal" align=3D"c=
enter" style=3D"text-align: center; margin: 0px;"><i><span lang=3D"EN-US" s=
tyle=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial =
Narrow',sans-serif; mso-ansi-language: EN-US;">Advisors</span></i><span lan=
g=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-fa=
mily: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-st=
yle: italic;">: Engelbert Mephu Nguifo (</span><a href=3D"mailto:engelbert.=
mephu_nguifo@uca.fr" target=3D"_blank"><span lang=3D"EN-US" style=3D"font-s=
ize: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sans-s=
erif; mso-ansi-language: EN-US; mso-bidi-font-style: italic;">engelbert.mep=
hu_nguifo@uca.fr</span></a><span lang=3D"EN-US" style=3D"font-size: 11.0pt;=
 mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sans-serif; mso-an=
si-language: EN-US; mso-bidi-font-style: italic;">)</span></p><p class=3D"M=
soNormal" align=3D"center" style=3D"text-align: center; margin: 0px;"><span=
 style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Aria=
l Narrow',sans-serif; mso-bidi-font-style: italic;">Vincent Barra (</span><=
a href=3D"mailto:vincent.barra@isima.fr" target=3D"_blank"><span style=3D"f=
ont-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',s=
ans-serif; mso-bidi-font-style: italic;">vincent.barra@isima.fr</span></a><=
span style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: '=
Arial Narrow',sans-serif; mso-bidi-font-style: italic;">)</span></p><p clas=
s=3D"MsoNormal" align=3D"center" style=3D"text-align: center; margin: 0px;"=
><span style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family:=
 'Arial Narrow',sans-serif; mso-bidi-font-style: italic;">&nbsp;</span></p>=
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align: center; margin=
: 0px;"><i><span style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; fo=
nt-family: 'Arial Narrow',sans-serif;">Location</span></i><span style=3D"fo=
nt-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sa=
ns-serif; mso-bidi-font-style: italic;">&nbsp;: LIMOS, UMR 6158 CNRS (</spa=
n><a href=3D"https://limos.fr/" target=3D"_blank"><span style=3D"font-size:=
 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sans-serif=
; mso-bidi-font-style: italic;">https://limos.fr/</span></a><span style=3D"=
font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',=
sans-serif; mso-bidi-font-style: italic;">)</span></p><p class=3D"MsoNormal=
" align=3D"center" style=3D"text-align: center; margin: 0px;"><span style=
=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narr=
ow',sans-serif; mso-bidi-font-style: italic;">Clermont-Auvergne University<=
/span></p><p class=3D"MsoNormal" align=3D"center" style=3D"text-align: cent=
er; margin: 0px;"><span style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.=
0pt; font-family: 'Arial Narrow',sans-serif; mso-bidi-font-style: italic;">=
Scientific Campus, 1 rue de la Ch=C3=A9barde</span></p><p class=3D"MsoNorma=
l" align=3D"center" style=3D"text-align: center; margin: 0px;"><span lang=
=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-fam=
ily: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-sty=
le: italic;">63178 AUBIERE =E2=80=93 FRANCE</span></p><p class=3D"MsoNormal=
" align=3D"center" style=3D"text-align: center; margin: 0px;"><span lang=3D=
"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family=
: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-style:=
 italic;">&nbsp;</span></p><p class=3D"MsoNormal" align=3D"center" style=3D=
"text-align: center; margin: 0px;"><i><span lang=3D"EN-US" style=3D"font-si=
ze: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sans-se=
rif; mso-ansi-language: EN-US;">Dates</span></i><span lang=3D"EN-US" style=
=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narr=
ow',sans-serif; mso-ansi-language: EN-US; mso-bidi-font-style: italic;">: S=
eptember 2019-August 2022</span></p><p class=3D"MsoNormal" style=3D"text-al=
ign: justify; line-height: 115%; margin: 0px;"><span lang=3D"EN-US" style=
=3D"font-size: 11.0pt; line-height: 115%; font-family: 'Arial Narrow',sans-=
serif; mso-ansi-language: EN-US;">&nbsp;</span></p><p class=3D"MsoNormal" s=
tyle=3D"text-align: justify; line-height: 115%; margin: 0px;"><span lang=3D=
"EN-US" style=3D"font-size: 11.0pt; line-height: 115%; font-family: 'Arial =
Narrow',sans-serif; mso-ansi-language: EN-US;">There is still a lack of com=
plete understanding of the complex pathways and mechanisms leading to centr=
al and peripheral drug-induced neurotoxicity. However, these adverse effect=
s are to a considerable extent (up to 25%) responsible for failure in clini=
cal trials, affecting volunteers or patients administered with experimental=
 drugs, and also, to some extent, albeit less than 1%, for hospitalizations=
 caused by hidden neurotoxic adverse effects of marketed drugs. </span></p>=
<p class=3D"MsoNormal" style=3D"text-align: justify; line-height: 115%; mar=
gin: 0px;"><b style=3D"mso-bidi-font-weight: normal;"><i style=3D"mso-bidi-=
font-style: normal;"><span lang=3D"EN-US" style=3D"font-size: 11.0pt; line-=
height: 115%; font-family: 'Arial Narrow',sans-serif; mso-ansi-language: EN=
-US;">&nbsp;</span></i></b></p><p class=3D"MsoNormal" style=3D"text-align: =
justify; line-height: 115%; margin: 0px;"><span lang=3D"EN-US" style=3D"fon=
t-size: 11.0pt; line-height: 115%; font-family: 'Arial Narrow',sans-serif; =
mso-ansi-language: EN-US;">The ambition of <b style=3D"mso-bidi-font-weight=
: normal;">NeuroDeRisk<a style=3D"mso-endnote-id: edn1;" href=3D"#_edn1" na=
me=3D"_ednref1" title=3D""><span class=3D"MsoEndnoteReference"><span style=
=3D"mso-special-character: footnote;"><span lang=3D"EN-US" style=3D"font-si=
ze: 11.0pt; font-family: 'Arial Narrow',sans-serif; mso-fareast-font-family=
: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Time=
s New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; ms=
o-fareast-language: EN-US; mso-bidi-language: AR-SA;">[i]</span></span></sp=
an></a></b> H2020 project is to bundle the scientific expertise of experime=
ntal and theoretical scientists and to collaborate with computer scientists=
 to address the challenge of preclinical prediction of neurotoxicity using =
a fully integrated approach: by linking unique expertise for building <i st=
yle=3D"mso-bidi-font-style: normal;">in vitro</i> and <i style=3D"mso-bidi-=
font-style: normal;">in vivo</i> models with <i style=3D"mso-bidi-font-styl=
e: normal;">in silico</i> prediction tools, the project will establish a no=
vel and validated toolbox for preclinical prediction of neurotoxicity in hu=
mans.<span style=3D"mso-spacerun: yes;">&nbsp;&nbsp; </span></span></p><p c=
lass=3D"MsoNormal" style=3D"text-align: justify; line-height: 115%; margin:=
 0px;"><span lang=3D"EN-US" style=3D"font-size: 11.0pt; line-height: 115%; =
font-family: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US;">&nbsp;</=
span></p><p class=3D"MsoNormal" style=3D"margin: 0px; text-align: justify; =
line-height: 115%;"><span lang=3D"EN-US" style=3D"font-size: 11.0pt; line-h=
eight: 115%; font-family: 'Arial Narrow',sans-serif; mso-ansi-language: EN-=
US;">The PhD subject is centered on <b style=3D"mso-bidi-font-weight: norma=
l;">the development of new machine learning strategies </b></span><b style=
=3D"mso-bidi-font-weight: normal;"><span lang=3D"EN-US" style=3D"font-size:=
 11.0pt; mso-bidi-font-size: 12.0pt; line-height: 115%; font-family: 'Arial=
 Narrow',sans-serif; mso-ansi-language: EN-US;">to optimize the identificat=
ion of predictive and alerting biomarkers of neurotoxicity</span></b><span =
lang=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; line=
-height: 115%; font-family: 'Arial Narrow',sans-serif; mso-ansi-language: E=
N-US;">. The objectives here will be:</span></p><p class=3D"MsoListParagrap=
hCxSpFirst" style=3D"margin: 0px; text-align: justify; text-indent: -18pt; =
line-height: 115%;"><span lang=3D"EN-US" style=3D"font-size: 11.0pt; mso-bi=
di-font-size: 12.0pt; line-height: 115%; font-family: 'Arial Narrow',sans-s=
erif; mso-fareast-font-family: 'Arial Narrow'; mso-bidi-font-family: 'Arial=
 Narrow'; mso-ansi-language: EN-US;"><span style=3D"mso-list: Ignore;">-<sp=
an style=3D"font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp; </span></span></span><span lang=3D"EN-US" style=3D"font-size: 1=
1.0pt; mso-bidi-font-size: 12.0pt; line-height: 115%; font-family: 'Arial N=
arrow',sans-serif; mso-ansi-language: EN-US;">to classify subjects (with re=
spect to neurotoxicity based on data collected by previous extensive behavi=
oral and biochemical signatures of neurotoxicity <i style=3D"mso-bidi-font-=
style: normal;">in vivo</i>, <i style=3D"mso-bidi-font-style: normal;">in v=
itro </i>and<i style=3D"mso-bidi-font-style: normal;"> ex vivo) </i>; </spa=
n></p><p class=3D"MsoListParagraphCxSpMiddle" style=3D"margin: 0px; text-al=
ign: justify; text-indent: -18pt; line-height: 115%;"><span lang=3D"EN-US" =
style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; line-height: 115%; =
font-family: 'Arial Narrow',sans-serif; mso-fareast-font-family: 'Arial Nar=
row'; mso-bidi-font-family: 'Arial Narrow'; mso-ansi-language: EN-US;"><spa=
n style=3D"mso-list: Ignore;">-<span style=3D"font: 7.0pt 'Times New Roman'=
;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><span la=
ng=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; line-h=
eight: 115%; font-family: 'Arial Narrow',sans-serif; mso-ansi-language: EN-=
US;">to compute low dimensional manifolds on which subjects lie, and be abl=
e to explore <span style=3D"mso-spacerun: yes;">&nbsp;</span>the trends and=
 directions of all possible neurotoxic effects in the derived space ;</span=
></p><p class=3D"MsoListParagraphCxSpLast" style=3D"margin: 0px; text-align=
: justify; text-indent: -18pt; line-height: 115%;"><span lang=3D"EN-US" sty=
le=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; line-height: 115%; fon=
t-family: 'Arial Narrow',sans-serif; mso-fareast-font-family: 'Arial Narrow=
'; mso-bidi-font-family: 'Arial Narrow'; mso-ansi-language: EN-US;"><span s=
tyle=3D"mso-list: Ignore;">-<span style=3D"font: 7.0pt 'Times New Roman';">=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><span lang=
=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-font-size: 12.0pt; line-hei=
ght: 115%; font-family: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US=
;">to be able to early predict biomarkers of neurotoxicity, based on only a=
 subset of data or on new features derived from the original data. </span><=
/p><p class=3D"MsoNormal" style=3D"margin: 0px; text-align: justify; line-h=
eight: 115%;"><span lang=3D"EN-US" style=3D"font-size: 11.0pt; mso-bidi-fon=
t-size: 12.0pt; line-height: 115%; font-family: 'Arial Narrow',sans-serif; =
mso-ansi-language: EN-US;">Both classical and innovative machine learning a=
lgorithms will be explored.</span></p><p class=3D"MsoNormal" style=3D"text-=
align: justify; line-height: 115%; margin: 0px;"><span lang=3D"EN-US" style=
=3D"font-size: 11.0pt; line-height: 115%; font-family: 'Arial Narrow',sans-=
serif; mso-ansi-language: EN-US;">&nbsp;</span></p><p class=3D"MsoNormal" s=
tyle=3D"text-align: justify; margin: 0px;"><span lang=3D"EN-US" style=3D"fo=
nt-size: 11.0pt; mso-bidi-font-size: 12.0pt; font-family: 'Arial Narrow',sa=
ns-serif; mso-ansi-language: EN-US;">Having selected the most promising bio=
marker candidates from in vivo, in vitro, and ex vivo studies, in silico pr=
ediction of biomarkers using a suitably modified version of a predictive pl=
atform will be performed.<span style=3D"mso-spacerun: yes;">&nbsp; </span>A=
dditional bioinformatics tools will be used in biomarker validation and pri=
oritization by other partners of the European project. </span></p><p class=
=3D"MsoNormal" style=3D"margin: 0px;"><span lang=3D"EN-US" style=3D"mso-ans=
i-language: EN-US;">&nbsp;</span></p><p class=3D"MsoNormal" style=3D"margin=
: 0px;"><span lang=3D"EN-US" style=3D"mso-ansi-language: EN-US;">&nbsp;</sp=
an></p><div style=3D"mso-element: endnote-list;"><br clear=3D"all"><hr alig=
n=3D"left" size=3D"1" width=3D"33%"><div style=3D"mso-element: endnote;" id=
=3D"edn1"><p class=3D"MsoEndnoteText" style=3D"margin: 0px;"><a style=3D"ms=
o-endnote-id: edn1;" href=3D"#_ednref1" name=3D"_edn1" title=3D""><span cla=
ss=3D"MsoEndnoteReference"><span style=3D"mso-special-character: footnote;"=
><span style=3D"font-size: 10.0pt; font-family: 'Calibri',sans-serif; mso-a=
scii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast=
-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-=
family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-langua=
ge: FR; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">[i]</span><=
/span></span></a><span lang=3D"EN-US" style=3D"mso-ansi-language: EN-US;"> =
NeuroDeRisk </span><span lang=3D"EN-US" style=3D"font-size: 11.0pt; font-fa=
mily: 'Arial Narrow',sans-serif; mso-ansi-language: EN-US;">(Neurotoxicity =
De-Risking in Preclinical Drug Discovery) is a H2020 European Project gathe=
ring 19 partners from 13 countries. </span><span lang=3D"EN-US" style=3D"ms=
o-ansi-language: EN-US;"></span></p></div></div> </div></div></div></div></=
div></div></div><br></div></div></body></html>
--=_810fdb11-1c3a-431f-9e54-ccfdcd2dd129--
